Use of preparations containing anti-cd44 antibodies in the treatment of certain tumours and the suppression of immune reactions
OwnerPeter Herrlich, Helmut Ponta +2inventors
InventorsPETER HERRLICH, HELMUT PONTA, JAN SIMON, JOHANNES WEISS
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of anti-CD44 antibodies of both the constant (sDC44) and the variable part of CD44 (vCD44) for treating certain tumours and other diseases associated with the degeneration and activation of Langerhans cells (LC) and dendritic cells (DC) inside a mammalian body, including humans, and for treating undesirable immune reactions. The invention further relates to an ex vivo cultivation process for producing dendritic cells.
Claims14
Use of anti-sCD44 and/or anti-vCD44 antibodies for producing a preparation for the prophylactic and therapeutic treatment of malignant diseases which are associated with the degeneration, activation or massive multiplication of Langerhans cells (LC) and/or dendritic cells (DC).
Use of anti-sCD44 antibodies for producing a preparation for the prophylactic and therapeutic treatment of diseases and conditions of a mammalian organism based on an immunoregulatory disorder or an undesirable or excessive immune reaction.
Use of anti-sCD44 antibodies for producing a preparation according to claim 10, characterised in that the immunoregulatory disorder or the undesirable or excessive immune reaction are allergic diseases, allergies of the delayed type, rejection of skin or organ transplants, autoimmune diseases, diseases of the rheumatic type, multiple sclerosis, psoriasis or atopical dermatitis.
Process for producing dendritic cells, characterised in that isolated monocytes are cultivated for a few days in a culture medium consisting of RPMI 1640, foetal calf serum, penicillin/streptomycin, a buffer consisting of an N-substituted aminosulphonic acid, non-essential amino acids, L-glutamine, GM-CSF and an interleukin, and then isolated.
Dependencies are inferred from the claim text.